Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4

Cancer Research

Volumn 74, Issue 17, 2014, Pages 4796-4810

  Von Roemeling, Christina A ^a   Radisky, Derek C ^a   Marlow, Laura A ^a   Cooper, Simon J ^a   Grebe, Stefan K ^b   Anastasiadis, Panagiotis Z ^a   Tun, Han W ^a   Copland, John A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; C REACTIVE PROTEIN; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 4; NERVE PROTEIN; NEURONAL PENTRAXIN;

CELL MOTION; CELL SURVIVAL; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NERVE TISSUE PROTEINS; RECEPTORS, AMPA;

EID: 84907059429     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0210     Document Type: Article

References (71)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763-71.
3. Lam JS, Shvarts O, Pantuck AJ. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol 2004;45:692-705.
4. Li G, Passebosc-Faure K, Lambert C, Gentil-Perret A, Blanc F, Oosterwijk E, et al. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Clin Cancer Res 2001;7:89-92.
5. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
6. Haddad H, Rini BI. Current treatment considerations in metastatic renal cell carcinoma. Curr Treat Options Oncol 2012;13: 212-29.
7. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial Sloan-Kettering cancer center experience. Clin Cancer Res 2004;10:6302S-3S.
8. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011;108:1556-63.
9. Romero IR, Morris C, Rodriguez M, Du Clos TW, Mold C. Inflammatory potential of C-reactive protein complexes compared to immune complexes. Clin Immunol Immunopathol. 1998;87:155-62.
10. Omeis IA, Hsu YC, Perin MS. Mouse and human neuronal pentraxin 1 (NPTX1): conservation, genomic structure, and chromosomal localization. Genomics 1996;36:543-5.
11. Hsu YC, Perin MS.Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization. Genomics 1995; 28:220-7.
12. Kirkpatrick LL, Matzuk MM, Dodds DC, Perin MS. Biochemical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calciumbinding protein 49 via NP1 and NP2. J Biol Chem 2000;275: 17786-92.
13. Tsui CC, Copeland NG, Gilbert DJ, Jenkins NA, Barnes C, Worley PF. Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity. J Neurosci 1996;16:2463-78.
14. Xu D, Hopf C, Reddy R, Cho RW, Guo L, Lanahan A, et al. Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. Neuron 2003;39: 513-28.
15. O'Brien RJ, Xu D, Petralia RS, Steward O, Huganir RL, Worley P. Synaptic clustering of AMPA receptors by the extracellular immediateearly gene product Narp. Neuron 1999;23:309-23.
16. O'Brien R, Xu D, Mi R, Tang X, Hopf C, Worley P. Synaptically targeted narp plays an essential role in the aggregation of AMPA receptors at excitatory synapses in cultured spinal neurons. J Neurosci 2002; 22:4487-98.
17. Sia GM, Beique JC, Rumbaugh G, Cho R, Worley PF, Huganir RL. Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. Neuron 2007;55:87-102.
18. Dodds DC, Omeis IA, Cushman SJ, Helms JA, Perin MS. Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49. J Biol Chem 1997;272:21488-94.
19. von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR,WuK, et al. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res 2013;19:2368-80.
20. Grossman HB, Wedemeyer G, Ren LQ. Human renal carcinoma: characterization of five new cell lines. J Surg Oncol 1985;28:237-44.
21. Coleman SK, Cai C, Mottershead DG, Haapalahti JP, Keinanen K. Surface expression of GluR-D AMPA receptor is dependent on an interaction between its C-terminal domain and a 4.1 protein. J Neurosci 2003;23:798-806.
22. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 2010;5:e10696.
23. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-8.
24. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, Flynn J, et al. Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One 2010;5.
25. Schmitz C, Perraud AL. The TRPM cation channels in the immune context. Curr Pharm Des 2005;11:2765-78.
26. Silei V, Fabrizi C, Venturini G, Tagliavini F, Salmona M, Bugiani O, et al. Measurement of intracellular calcium levels by the fluorescent Ca(2+) indicator Calcium-Green. Brain Res Brain Res Protoc 2000;5:132-4.
27. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011;20:511-23.
28. Kort EJ, Farber L, Tretiakova M, Petillo D, Furge KA, Yang XJ, et al. The E2F3-Oncomir-1 axis is activated in Wilms' tumor. Cancer Res 2008;68:4034-8.
29. Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, et al. Regulation of endocytosis via the oxygen-sensing pathway. Nat Med 2009;15:319-24.
30. Stickel JS, Weinzierl AO, Hillen N, Drews O, Schuler MM, Hennenlotter J, et al. HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother 2009;58:1407-17.
31. Yusenko MV, Zubakov D, Kovacs G. Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours. Int J Biol Sci 2009;5:517-27.
32. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005;11:5730-9.
33. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003;3:31.
34. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007;13:4740-9.
35. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012;44:751-9.
36. (ICG) TIGC. The expO project (Expression Project for Oncology). Available from: www.intgen.org. [Accessed Date Aug 29, 2013].
37. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003;162:925-32.
38. Beleut M, Zimmermann P, Baudis M, Bruni N, Buhlmann P, Laule O, et al. Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. BMC Cancer 2012;12:310.
39. Tan X, Zhai Y, Chang W, Hou J, He S, Lin L, et al. Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma. Int J Cancer 2008;123:1080-8.
40. Cifola I, Spinelli R, Beltrame L, Peano C, Fasoli E, Ferrero S, et al. Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 2008;7:6.
41. Williams AA, Higgins JP, Zhao H, Ljunberg B, Brooks JD. CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol 2009;9:9.
42. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol 2003;19:541-64.
43. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-81.
44. Chen SH, Lin CY, Lee LT, Chang GD, Lee PP, Hung CC, et al. Upregulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells. Anticancer Res 2010;30:4177-86.
45. Steffens S, Schrader AJ, Vetter G, Eggers H, Blasig H, Becker J, et al. Fibronectin 1 protein expression in clear cell renal cell carcinoma. Oncol Lett 2012;3:787-90.
46. Mansour M, Nagarajan N, Nehring RB, Clements JD, Rosenmund C. Heteromeric AMPA receptors assemble with a preferred subunit stoichiometry and spatial arrangement. Neuron 2001;32:841-53.
47. Schorge S, Colquhoun D. Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J Neurosci 2003;23:1151-8.
48. Chimirri A, De Sarro G, De Sarro A, Gitto R, Grasso S, Quartarone S, et al. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J Med Chem 1997;40:1258-69.
49. Ishiuchi S, Yoshida Y, Sugawara K, Aihara M, Ohtani T, Watanabe T, et al. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 2007;27:7987-8001.
50. Fortin DA, Davare MA, Srivastava T, Brady JD, Nygaard S, Derkach VA, et al. Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I. J Neurosci 2010;30:11565-75.
51. Haribabu B, Hook SS, Selbert MA, Goldstein EG, Tomhave ED, Edelman AM, et al. Human calcium-calmodulin dependent protein kinase I: cDNA cloning, domain structure and activation by phosphorylation at threonine-177 by calcium-calmodulin dependent protein kinase I kinase. EMBO J 1995;14:3679-86.
52. Hart JR, Vogt PK. Phosphorylation of AKT: a mutational analysis. Oncotarget 2011;2:467-76.
53. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575-85.
54. Chang AC, Jellinek DA, Reddel RR. Mammalian stanniocalcins and cancer. Endocr Relat Cancer 2003;10:359-73.
55. Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res 2012;129:S30-7.
56. Li M, Mukasa A, IndaMM,Zhang J, Chin L, Cavenee W, et al. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med 2011;208:2657-73.
57. Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest 2010;120:2684-98.
58. Zhang L, Gao J, Li L, Li Z, Du Y, Gong Y. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Mol Biol Rep 2011;38:4903-11.
59. Swanson GT, Kamboj SK, Cull-Candy SG. Single-channel properties of recombinant AMPA receptors depend on RNA editing, splice variation, and subunit composition. J Neurosci 1997;17: 58-69.
60. Song I, Huganir RL. Regulation of AMPA receptors during synaptic plasticity. Trends Neurosci 2002;25:578-88.
61. Marin O, Rubenstein JL. Cell migration in the forebrain. Annu Rev Neurosci 2003;26:441-83.
62. Manent JB, Jorquera I, Ben-Ari Y, Aniksztejn L, Represa A. Glutamate acting on AMPA but not NMDA receptors modulates the migration of hippocampal interneurons. J Neurosci 2006;26:5901-9.
63. Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, et al. Understanding familial and non-familial renal cell cancer. Hum Mol Genet 2002;11:2489-98.
64. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H, et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 2002;8:971-8.
65. Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via b1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol 2009;11:260-73.
66. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007;67:9463-71.
67. Rzeski W, Ikonomidou C, Turski L. Glutamate antagonists limit tumor growth. Biochem Pharmacol 2002;64:1195-200.
68. Haas HS, Pfragner R, Tabrizi-Wizsy NG, Rohrer K, Lueftenegger I, Horwath C, et al. The influence of glutamate receptors on proliferation and metabolic cell activity of neuroendocrine tumors. Anticancer Res 2013;33:1267-72.
69. Prickett TD, Samuels Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res 2012;18:4240-6.
70. Wei C, Wang X, Chen M, Ouyang K, Song LS, Cheng H. Calcium flickers steer cell migration. Nature 2009;457:901-5.
71. Wei C, Wang X, Zheng M, Cheng H. Calcium gradients underlying cell migration. Curr Opin Cell Biol 2012;24:254-61.